HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
- Conditions
- HER2 Positive or Suspicious Positive Tumors
- Registration Number
- NCT06548529
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria:<br><br> 1. Aged # 18 years old; ECOG 0 or 1;<br><br> 2. Is unresectable or metastatic;<br><br> 3. Patients with HER2 positive or suspicious positive tumors;<br><br> 4. was previously treated with trastuzumab and taxane in the advanced setting or<br> progressed within 6 months after neoadjuvant or adjuvant treatment involving a<br> regimen including trastuzumab and taxane;<br><br> 5. Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;<br><br> 6. Receives anti-HER2 ADC treatment<br><br> 7. Life expectancy > 3 months<br><br>Exclusion Criteria:<br><br> 1. Significant hepatic or renal dysfunction;<br><br> 2. Is pregnant or ready to pregnant;<br><br> 3. Cannot keep their states for half an hour;<br><br> 4. Refused to join the clinical research;<br><br> 5. Suffering from claustrophobia or other mental disorders;<br><br> 6. Any other situation that researchers considered it unsuitable to participate in the<br> trial.
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SUV
- Secondary Outcome Measures
Name Time Method